AzTrials
AzTrials

Thin Gingival BiotypeNCT07317856

Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype

A study testing Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA) in people with Thin Gingival Biotype, run by University of Baghdad at 1 site in Iraq.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This randomized controlled trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines and the Declaration of Helsinki ethical principles for medical research. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Thin Gingival Biotype
What is being tested?
Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteIraq
Study dates
Jan 2026to Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults aged ≥18 years from both sexes
  • Systemically healthy individuals with no history of chronic systemic diseases.
  • Participants with positive periodontal probe transparency in anterior teeth.
  • Adequate oral hygiene (full-mouth plaque score ≤20%).
  • Non-smokers or former smokers who quit ≥12 months prior to enrollment.
  • Willingness to comply with study procedures, attend follow-up visits, and provide written informed consent.

Who cannot join

  • Pregnancy or lactation.
  • Use of medications affecting periodontal status or wound healing (e.g., systemic corticosteroids, bisphosphonates) within the past six months
  • History of periodontal surgery or soft-tissue augmentation procedures at the target sites
  • Active periodontal disease (probing depth >3 mm, clinical attachment loss >2 mm) or gingival inflammation (bleeding on probing ≥ 10%).
  • Untreated carious lesions or periapical pathology in the study area.
  • Systemic conditions that impair healing (e.g., uncontrolled diabetes mellitus, immunocompromised states).
Show all 9Show fewer
  • Use of anti-inflammatory or anticoagulant medications within two weeks prior to treatment.
  • Known allergy to hyaluronic acid or components of the microneedling device.
  • Presence of heavy gingival pigmentation at the target sites.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Murtadha Mohammed Humadi Dentist, B.D.S contact

009647731843878

Mortada.naima2405@codental.uobaghdad.edu.iq

Iraq1 site
  • University of Baghdad

    Baghdad, 10047

    College of Dentistry, University of Baghdad, 0096414169394, master@codental.uobaghdad.edu.iq

Other trials in Iraq

About this study

Official title: Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype: A Split- Mouth Randomized Clinical Trial

This randomized controlled trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines and the Declaration of Helsinki ethical principles for medical research. The study complies with Good Clinical Practice (GCP) standards and will be prospectively registered with ClinicalTrials.gov to ensure transparency and accountability. A crossover design is implemented to ensure all participants receive both treatment modalities-microneedling (MN) alone and microneedling combined with injectable hyaluronic acid (MN + HA)-following an appropriate washout period, promoting equitable access while maintaining scientific rigor through within-subject comparisons.

Baseline Preparation

Read more

All enrolled participants receive comprehensive periodontal therapy at baseline, including supragingival and subgingival scaling using ultrasonic instrumentation combined with hand instruments. Standardized oral hygiene protocols are established with identical oral care products provided to each subject, including a soft-bristled toothbrush and interdental cleaning aids. All participants receive instruction in proper brushing technique with emphasis on twice-daily maintenance to ensure consistent plaque control throughout the trial.

Microneedling Intervention

The MN intervention comprises three sessions spaced seven days apart. Following baseline clinical assessment (plaque index, bleeding on probing, probing depth, clinical attachment level, keratinized tissue width, and gingival thickness) with standardized photographs, topical anesthesia is applied for one minute followed by infiltration anesthesia with 2% lidocaine with 1:100,000 epinephrine. The Dr. Pen Ultima A6 with a 24-pin cartridge is vertically inserted through keratinized gingiva until bone contact is achieved, treating from the mesial central incisor to the distal canine. Treatment ends when uniform pin-point bleeding is achieved. Post-procedure care includes gentle saline rinse, avoidance of brushing for 24 hours, twice-daily 0.12% chlorhexidine mouthwash for seven days, and avoidance of NSAIDs. Clinical reassessment occurs at 3 and 6 months.

Microneedling Plus Hyaluronic Acid Intervention

Following identical baseline assessment, anesthesia, and microneedling as the MN group, cross-linked hyaluronic acid (16-20 mg/mL, 200-400 µm particle size) is injected using 30-gauge needles (8 mm) with 1 mL insulin syringes. Two anatomical sites per area receive injections: 3 mm apical to the free gingival margin and apical to the mucogingival junction. The needle is inserted at 45 degrees, advanced 2-3 mm until blanching occurs, with a total volume of 0.04 mL per site (0.02 mL per point) at a rate not exceeding 0.01 mL per 10 seconds. Post-injection circular massage for 2-3 minutes ensures uniform distribution. Three sessions are performed seven days apart with identical post-procedure care and follow-up assessments at 3 and 6 months.

Outcome Measures

The primary outcome is the change in gingival thickness (millimeters) at treated sites from baseline to 6 months post-intervention, measured using transgingival probing. Secondary outcomes include changes in keratinized gingiva width, periodontal parameters (Plaque Index, Bleeding on Probing, Probing Pocket Depth, and Clinical Attachment Level), and patient-reported outcomes for pain, swelling, discomfort, and bleeding measured using visual analog scales at 2, 24, and 48 hours post-intervention. This comprehensive protocol ensures robust evaluation of both objective tissue augmentation and subjective patient experiences across both treatment modalities.

Being tested
Microneedling (MN), Microneedling + Injectable Hyaluronic Acid (MN + HA)
Keywords
Hyaluronic acid, microneedling, soft tissue regeneration, soft tissue augmentation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Microneedling (MN)Procedure or surgery

    A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine. The treatment endpoint is identified as uniform pin-point bleeding, which is easily controlled with gentle pressure. The microneedling procedure will be repeated for three sessions, with each session spaced 7 days apart. This protocol ensures consistent intervention dosage and timing to optimize gingival augmentation outcomes while allowing adequate healing time between sessions.

  • Microneedling + Injectable Hyaluronic Acid (MN + HA)Combination product

    A derma pen (Dr. Pen Ultima A6) with 24-pin cartridge will be used for microneedling. The device will be vertically inserted through the keratinized gingiva at each treatment site until contact with the underlying hard tissue (bone) is reached. Treatment will extend from the mesial line angle of the central incisor to the distal line angle of the canine.The hyaluronic acid injection protocol for gingival augmentation utilizes cross-linked hyaluronic acid at 16-20 mg/mL concentration with 200-400 μm particle size, delivered via sterile pre-filled syringes using 30-gauge microneedles (8mm) with 1mL insulin syringes marked at 0.02mL intervals. Following topical anesthetic application for 2-3 minutes, the injection technique targets two anatomical sites per treatment area: the first point located 3mm apical to the free gingival margin and the second point apical to the mucogingival junction. Post-injection gentle circular massage for 2-3 minutes ensures uniform distribution of the material

Study groups in NCT07317856
Study groupRoleWhat they receive
Microneedling (MN) GroupActive comparatorControl group
Receives: Procedure: Microneedling (MN)
Microneedling + Injectable Hyaluronic Acid (MN + HA) GroupExperimentalTest group
Receives: Combination Product: Microneedling + Injectable Hyaluronic Acid (MN + HA)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in gingival thickness

    The primary outcome measure is the change in gingival thickness (in millimeters) at treated sites from baseline to 6 months post-intervention, as determined by transgingival probing method.

    Measured: 6 months

Secondary outcomes (6)
  1. Change in width of keratinized gingiva

    Measured: 6 months

  2. Plaque Index (PI)

    Measured: 6 months

  3. Bleeding on probing (BOP)

    Measured: 6 months

  4. Clinical attachment level (CAL)

    Measured: 6 months

  5. Change in probing depth

    Measured: 6 months

  6. Patient-reported outcomes

    Patient-reported outcomes assessed via visual analog scales for pain, swelling, discomfort and bleeding at 2 hours, 8 hours, 24 hours, and 48 hours following each intervention session.

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2026
  2. Study startJan 2026 (estimated)
  3. Primary completionSep 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study will be a 6-month follow-up, split mouth, double blind, prospective randomized controlled Clinical trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07317856
Sponsor's protocol ID
1114
Status last verified
Dec 2025
First submitted
19 Dec 2025
Last updated
5 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Microneedling (MN) and Microneedling + Injectable Hyaluronic Acid (MN + HA) in people with Thin Gingival Biotype, run by University of Baghdad at 1 site in Iraq.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Murtadha Mohammed Humadi Dentist, B.D.S (009647731843878, Mortada.naima2405@codental.uobaghdad.edu.iq), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in gingival thickness (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in